These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

783 related articles for article (PubMed ID: 26974374)

  • 1. Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches.
    Salahuddin P; Fatima MT; Abdelhameed AS; Nusrat S; Khan RH
    Eur J Med Chem; 2016 May; 114():41-58. PubMed ID: 26974374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.
    Meredith SC
    Ann N Y Acad Sci; 2005 Dec; 1066():181-221. PubMed ID: 16533927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Amyloid-β Component of Human α-Synuclein Oligomers Induces Formation of New Aβ Oligomers: Insight into the Mechanisms That Link Parkinson's and Alzheimer's Diseases.
    Atsmon-Raz Y; Miller Y
    ACS Chem Neurosci; 2016 Jan; 7(1):46-55. PubMed ID: 26479553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How do membranes initiate Alzheimer's Disease? Formation of toxic amyloid fibrils by the amyloid β-protein on ganglioside clusters.
    Matsuzaki K
    Acc Chem Res; 2014 Aug; 47(8):2397-404. PubMed ID: 25029558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stabilization of α-Synuclein Fibril Clusters Prevents Fragmentation and Reduces Seeding Activity and Toxicity.
    Lam HT; Graber MC; Gentry KA; Bieschke J
    Biochemistry; 2016 Feb; 55(4):675-85. PubMed ID: 26799377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers.
    Ugalde CL; Finkelstein DI; Lawson VA; Hill AF
    J Neurochem; 2016 Oct; 139(2):162-180. PubMed ID: 27529376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of amyloids in Alzheimer's and Parkinson's diseases.
    Salahuddin P; Fatima MT; Uversky VN; Khan RH; Islam Z; Furkan M
    Int J Biol Macromol; 2021 Nov; 190():44-55. PubMed ID: 34480905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Pairs of Toxic and Nontoxic Misfolded Protein Oligomers Elucidates the Structural Determinants of Oligomer Toxicity in Protein Misfolding Diseases.
    Limbocker R; Cremades N; Cascella R; Tessier PM; Vendruscolo M; Chiti F
    Acc Chem Res; 2023 Jun; 56(12):1395-1405. PubMed ID: 37071750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformation-dependent scFv antibodies specifically recognize the oligomers assembled from various amyloids and show colocalization of amyloid fibrils with oligomers in patients with amyloidoses.
    Zhang X; Sun XX; Xue D; Liu DG; Hu XY; Zhao M; Yang SG; Yang Y; Xia YJ; Wang Y; Liu RT
    Biochim Biophys Acta; 2011 Dec; 1814(12):1703-12. PubMed ID: 21979582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidating the Structures of Amyloid Oligomers with Macrocyclic β-Hairpin Peptides: Insights into Alzheimer's Disease and Other Amyloid Diseases.
    Kreutzer AG; Nowick JS
    Acc Chem Res; 2018 Mar; 51(3):706-718. PubMed ID: 29508987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
    Hashimoto M; Rockenstein E; Crews L; Masliah E
    Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterologous amyloid seeding: revisiting the role of acetylcholinesterase in Alzheimer's disease.
    Jean L; Thomas B; Tahiri-Alaoui A; Shaw M; Vaux DJ
    PLoS One; 2007 Jul; 2(7):e652. PubMed ID: 17653279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Seeds to Fibrils and Back: Fragmentation as an Overlooked Step in the Propagation of Prions and Prion-Like Proteins.
    Marrero-Winkens C; Sankaran C; Schätzl HM
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32927676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer's disease and other diseases with amyloid deposits.
    Stefani M
    Prog Neurobiol; 2012 Dec; 99(3):226-45. PubMed ID: 22450705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atomic force microscopy to study molecular mechanisms of amyloid fibril formation and toxicity in Alzheimer's disease.
    Drolle E; Hane F; Lee B; Leonenko Z
    Drug Metab Rev; 2014 May; 46(2):207-23. PubMed ID: 24495298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.
    Ciechanover A; Kwon YT
    Exp Mol Med; 2015 Mar; 47(3):e147. PubMed ID: 25766616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities.
    Foguel D; Suarez MC; Ferrão-Gonzales AD; Porto TC; Palmieri L; Einsiedler CM; Andrade LR; Lashuel HA; Lansbury PT; Kelly JW; Silva JL
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9831-6. PubMed ID: 12900507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidating the Role of Lipids in the Aggregation of Amyloidogenic Proteins.
    Kurouski D
    Acc Chem Res; 2023 Nov; 56(21):2898-2906. PubMed ID: 37824095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of amyloid formation and membrane interaction with amyloidogenic proteins.
    Murphy RM
    Biochim Biophys Acta; 2007 Aug; 1768(8):1923-34. PubMed ID: 17292851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity.
    Fändrich M
    J Mol Biol; 2012 Aug; 421(4-5):427-40. PubMed ID: 22248587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.